SCHEMBL1099282

SCHEMBL1099282

Cc1c(N(CCCCC(F)(F)F)S(=O)(=O)c2ccc(N3CCSCC3)cc2)sc2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 6/20 0.43
HTR7 P34969 4/20 0.37
HTR2A P28223 3/20 0.37
HTR1A P08908 2/20 0.37
DRD2 P14416 2/20 0.37
HTR6 P50406 2/20 0.37
CNR2 P34972 4/20 0.35
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
CNR1 P21554 2/20 0.32
HTR2C P28335 1/20 0.32
MAPT P10636 1/20 0.32
RORC P51449 2/20 0.32
PHOSPHO1 Q8TCT1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1098906 0.92 TRPM8 (0.44) TRPM8HTR7HTR2AHTR1ADRD2
SCHEMBL1098475 0.91 TRPM8 (0.43) TRPM8HTR7HTR2AHTR1ADRD2
SCHEMBL1098856 0.85 TRPM8 (0.51) TRPM8HTR7HTR2AHTR1ADRD2
SCHEMBL1098150 0.85 TRPM8 (0.41) TRPM8HTR7HTR2AHTR1ADRD2
SCHEMBL1100541 0.82 TRPM8 (0.47) TRPM8HTR7HTR2AHTR1ADRD2
SCHEMBL1099774 0.82 TRPM8 (0.52) TRPM8HTR7HTR2AHTR1ADRD2
SCHEMBL1107227 0.81 TRPM8 (0.46) TRPM8ESR1ESR2RORC
SCHEMBL1099477 0.81 TRPM8 (0.64) TRPM8
SCHEMBL1099583 0.79 TRPM8 (0.56) TRPM8RORC
SCHEMBL1099626 0.78 TRPM8 (0.55) TRPM8ESR1ESR2MAPTRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885HTR7 633/4885HTR2A 319/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885HTR7 633/4885HTR2A 319/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885HTR7 633/4885HTR2A 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.